A Phase 1 interventional study of LY3844583 and LY3844583 in Healthy and Dermatitis, Atopic, sponsored by Eli Lilly and Company. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) · Part A: Placebo IV (SAD - Cohort 4-5) · Part A: 30 mg LY3844583 SC (SAD - Cohort 1) · Part A: 100 mg LY3844583 SC (SAD - Cohort 2) · Part A: 300 mg LY3844583 SC (SAD - Cohort 3) · Part A: 300 mg LY3844583 IV (SAD - Cohort 4) · Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) · Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) · Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) · Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) · Part C: Placebo IV Q2W · Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
LY3844583 (Part A) · LY3844583 (Part B) · LY3844583 (Part C) · Placebo (Part A) · Placebo (Part B) · Placebo (Part C)
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dermatitis, Atopic by Eli Lilly and Company — 1 open to participants now, 2 under way, 2 of them phase 3. Dermatitis, Atopic · Eli Lilly and Company.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 26th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 1, and was the 23rd registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 30 studies in Dermatitis, Atopic by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is close to the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 283 across the 30 interventional studies. Of the 28 that completed or were terminated, 25 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 542 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis (AtD). The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 85, 113, and 183 days with 10, 18, and 14 visits for each participant in parts A, B, and C, respectively.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy participants (Parts A and B):
Atopic dermatitis participants (Part C):
Exclusion Criteria:
All participants:
Atopic dermatitis participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants received a single matching dose of Placebo via subcutaneous (SC) injection on Day 1.
Drug: Placebo
Healthy participants received a single matching dose of Placebo via intravenous (IV) infusion on Day 1.
Drug: Placebo
Healthy participants received a single dose of 30 milligrams (mg) LY3844583 via SC injection on Day 1.
Drug: LY3844583
Healthy participants received a single dose of 100 mg LY3844583 via SC injection on Day 1.
Drug: LY3844583
Healthy participants received a single dose of 300 mg LY3844583 via SC injection on Day 1.
Drug: LY3844583
Healthy participants received a single dose of 300 mg LY3844583 via IV infusion on Day 1.
Drug: LY3844583
Healthy participants received a single dose of 1000 mg LY3844583 via IV infusion on Day 1.
Drug: LY3844583
Healthy participants received a matching dose of Placebo via IV infusion once every 2 weeks (Q2W) on Days 1, 15, and 29 in Cohort 1, or once every week (QW) on Days 1, 8, 15, 22, and 29 in Cohort 2.
Drug: Placebo
Healthy participants received 300 mg LY3844583 via IV infusion Q2W on Days 1, 15, and 29.
Drug: LY3844583
Healthy participants received 1000 mg LY3844583 via IV infusion QW on Days 1, 8, 15, 22, and 29.
Drug: LY3844583
Participants with Atopic Dermatitis (AtD) received a matching dose of Placebo via IV infusion Q2W for 12 weeks.
Drug: Placebo
Participants with AtD received 1000 mg LY3844583 via IV infusion Q2W for 12 weeks.
Drug: LY3844583
Administered SC
Administered IV
Administered SC
Administered IV
Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
* An AE was any untoward medical occurrence in a participant who was administered an investigational product that did not necessarily have a causal relationship with the treatment. A TEAE was defined as an AE that occurred post-dose or was present prior to dosing and became more severe post-dose. * An SAE was any AE from the study that resulted in one of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (i.e., immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that might not have been immediately life-threatening or resulted in death or hospitalization but might have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above. * A summary of SAEs and other non-serious AEs, regardless of causality, is located in the reported Adverse Events section of this record.
Time frame: Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)
PK: Cmax of LY3844583 in Part A (SAD)
Time frame: Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)
PK: AUC(0-inf) of LY3844583 in Part A (SAD)
Time frame: Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
PK: Cmax of LY3844583 - Part B (MAD - Cohort 1)
PK: Cmax of LY3844583 in Part B (MAD - Cohort 1)
Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
PK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)
PK: AUCτ of LY3844583 (τ = 336 hrs) in Part B (MAD - Cohort 1)
Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose)
PK: Cmax of LY3844583 - Part B (MAD - Cohort 2)
PK: Cmax of LY3844583 in Part B (MAD - Cohort 2)
Time frame: Part B (MAD - Cohort 2): Day 1 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
PK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)
PK: AUCτ of LY3844583 (τ = 168 hrs) in Part B (MAD - Cohort 2). For Day 29, no PK samples were collected at 168 hours post dose, so data up to 144 hours post-dose were reported and used for AUC 0-τ parameter assessments.
Time frame: Part B (MAD - Cohort 2): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144 hours postdose)
PK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
PK: Cmax of LY3844583 in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
PK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
PK: AUCτ of LY3844583 (τ = 336 hours) in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1).For Day 85: No PK samples were collected beyond 72 hours post-dose, so data up to 72 hours post-dose were reported and used for AUC 0-τ parameter assessments.
Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
Part C of the trial had been terminated early as, based on an analysis of the observed efficacy data from previous cohorts, the sponsor had determined that the results did not support continuing the trial.
| Milestone | Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 5 | 6 | 6 | 6 | 6 | 11 | 4 | 6 | 6 | 6 | 18 |
| Received at least one dose of study drug | 6 | 5 | 6 | 6 | 6 | 6 | 11 | 4 | 6 | 6 | 6 | 18 |
| Completed | 6 | 5 | 6 | 6 | 6 | 6 | 11 | 4 | 6 | 6 | 2 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 9 |
* An AE was any untoward medical occurrence in a participant who was administered an investigational product that did not necessarily have a causal relationship with the treatment. A TEAE was defined as an AE that occurred post-dose or was present prior to dosing and became more severe post-dose. * An SAE was any AE from the study that resulted in one of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (i.e., immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that might not have been immediately life-threatening or resulted in death or hospitalization but might have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above. * A summary of SAEs and other non-serious AEs, regardless of causality, is located in the reported Adverse Events section of this record.
| Participants | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 0 | 0 | 1 | 0 | 0 | 3 | 6 | 0 | 1 | 2 | 4 | 10 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PK: Cmax of LY3844583 in Part A (SAD)
| nanograms per milliliter (ng/mL) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD) | 3190 ± 29 | 10800 ± 34 | 51400 ± 27 | 118000 ± 26 | 410000 ± 17 |
PK: AUC(0-inf) of LY3844583 in Part A (SAD)
| hours*nanograms per milliliter (h*ng/mL) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD) | 984000 ± 27 | 4330000 ± 37 | 19700000 ± 26 | 24100000 ± 19 | 96700000 ± 23 |
PK: Cmax of LY3844583 in Part B (MAD - Cohort 1)
| nanograms per milliliter (ng/mL) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) |
|---|---|
| Day 1 | 129000 ± 15 |
| Day 29 | 156000 ± 25 |
PK: AUCτ of LY3844583 (τ = 336 hrs) in Part B (MAD - Cohort 1)
| hours*nanograms per milliliter (h*ng/mL) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) |
|---|---|
| Day 1 | 16000000 ± 23 |
| Day 29 | 23900000 ± 30 |
PK: Cmax of LY3844583 in Part B (MAD - Cohort 2)
| nanograms per milliliter (ng/mL) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) |
|---|---|
| Day 1 | 509000 ± 19 |
| Day 29 | 888000 ± 9 |
PK: AUCτ of LY3844583 (τ = 168 hrs) in Part B (MAD - Cohort 2). For Day 29, no PK samples were collected at 168 hours post dose, so data up to 144 hours post-dose were reported and used for AUC 0-τ parameter assessments.
| hours*nanograms per milliliter (h*ng/mL) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) |
|---|---|
| Day 1 | 42900000 ± 14 |
| Day 29 | 91800000 ± 13 |
PK: Cmax of LY3844583 in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
| nanograms per milliliter (ng/mL) | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) |
|---|---|
| Day 1 | 449000 ± 19 |
| Day 85 | 683000 ± 11 |
PK: AUCτ of LY3844583 (τ = 336 hours) in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1).For Day 85: No PK samples were collected beyond 72 hours post-dose, so data up to 72 hours post-dose were reported and used for AUC 0-τ parameter assessments.
| hours*nanograms per milliliter (h*ng/mL) | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) |
|---|---|
| Day 1 | 57000000 ± 20 |
| Day 85 | 112000000 ± 12 |
Collected over Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo SC ( SAD -Cohort 1-3) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: Placebo IV (SAD - Cohort 4-5) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Part B: Placebo IV (MAD - Cohort 1-2) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part C: Placebo IV Q2W | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | 0/18 (0%) | 0/18 (0%) | 10/18 (55.6%) |
| Event | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 3/11 | 0/4 | 0/6 | 0/6 | 0/6 | 0/18 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 1/6 | 4/18 |
| Conjunctival haemorrhageEye disorders | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 1/6 | 0/6 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/5 | 1/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 0/6 | 0/18 |
| Influenza like illnessGeneral disorders | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 1/6 | 0/11 | 0/4 | 0/6 | 0/6 | 0/6 | 0/18 |
| Vessel puncture site erythemaGeneral disorders | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 1/6 | 0/6 | 0/6 | 0/18 |
| NasopharyngitisInfections and infestations | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 0/6 | 3/18 |
| Oral herpesInfections and infestations | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 1/6 | 0/18 |
| Glucose urine presentInvestigations | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 1/6 | 0/18 |
| Grip strength decreasedInvestigations | 0/6 | 0/5 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/4 | 0/6 | 0/6 | 1/6 | 0/18 |
All randomized participants.
| Age, Continuous(years) | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 42.3 ± 13.4 | 37.4 ± 18.1 | 35.2 ± 11.6 | 40.0 ± 15.3 | 39.3 ± 5.0 | 38.3 ± 15.6 | 42.1 ± 15.2 | 45.8 ± 15.7 | 41.8 ± 9.1 | 38.8 ± 13.3 | 37.2 ± 10.1 | 37.0 ± 9.4 | 39.3 ± 12.0 |
| Sex: Female, Male(Participants) | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 1 | 0 | 1 | 4 | 1 | 0 | 1 | 2 | 10 | 23 |
| Male | 6 | 3 | 5 | 5 | 6 | 5 | 7 | 3 | 6 | 5 | 4 | 8 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 1 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 11 |
| Not Hispanic or Latino | 5 | 5 | 3 | 5 | 4 | 6 | 10 | 3 | 4 | 6 | 6 | 18 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 2 | 3 | 0 | 1 | 0 | 3 | 8 | 1 | 1 | 5 | 6 | 18 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 12 |
| White | 2 | 2 | 5 | 2 | 4 | 1 | 2 | 3 | 4 | 0 | 0 | 0 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Placebo SC ( SAD -Cohort 1-3) | Part A: Placebo IV (SAD - Cohort 4-5) | Part A: 30 mg LY3844583 SC (SAD - Cohort 1) | Part A: 100 mg LY3844583 SC (SAD - Cohort 2) | Part A: 300 mg LY3844583 SC (SAD - Cohort 3) | Part A: 300 mg LY3844583 IV (SAD - Cohort 4) | Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) | Part B: Placebo IV (MAD - Cohort 1-2) | Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) | Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) | Part C: Placebo IV Q2W | Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 5 | 6 | 6 | 6 | 6 | 11 | 4 | 6 | 6 | 0 | 0 | 62 |
| Japan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 18 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Jan 2024, 17 months.
Results were first posted in Oct 2026, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) · Part A: Placebo IV (SAD - Cohort 4-5) · Part A: 30 mg LY3844583 SC (SAD - Cohort 1) · Part A: 100 mg LY3844583 SC (SAD - Cohort 2) · Part A: 300 mg LY3844583 SC (SAD - Cohort 3) · Part A: 300 mg LY3844583 IV (SAD - Cohort 4) · Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) · Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) · Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) · Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) · Part C: Placebo IV Q2W · Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
LY3844583 (Part A) · LY3844583 (Part B) · LY3844583 (Part C) · Placebo (Part A) · Placebo (Part B) · Placebo (Part C)
Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) · Part A: Placebo IV (SAD - Cohort 4-5) · Part A: 30 mg LY3844583 SC (SAD - Cohort 1) · Part A: 100 mg LY3844583 SC (SAD - Cohort 2) · Part A: 300 mg LY3844583 SC (SAD - Cohort 3) · Part A: 300 mg LY3844583 IV (SAD - Cohort 4) · Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) · Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) · Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) · Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) · Part C: Placebo IV Q2W · Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
LY3844583 (Part A) · LY3844583 (Part B) · LY3844583 (Part C) · Placebo (Part A) · Placebo (Part B) · Placebo (Part C)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.